Jazz Pharmaceuticals (JAZZ) Revenue
Jazz Pharmaceuticals (JAZZ) has trailing twelve month revenue of $4.16B. Revenue has grown 4.1% year-over-year. The company trades on the NASDAQ with a market cap of $11.60B.
TTM Revenue
$4.16B
YoY Growth
+4.1%
Latest Quarter
$1.13B
Quarterly Revenue
| Period | Revenue | Cost of Revenue | Gross Profit | Margin |
|---|---|---|---|---|
| FY2025 Q3 | $1.13B | $0 | $0 | 0.0% |
| FY2025 Q2 | $1.05B | $0 | $0 | 0.0% |
| FY2025 Q1 | $897.8M | $0 | $0 | 0.0% |
| FY2024 Q4 | $1.09B | $0 | $0 | 0.0% |
| FY2024 Q3 | $1.05B | $0 | $0 | 0.0% |
| FY2024 Q2 | $1.02B | $0 | $0 | 0.0% |
| FY2024 Q1 | $902.0M | $0 | $0 | 0.0% |
| FY2023 Q4 | $1.01B | $0 | $0 | 0.0% |
Frequently Asked Questions
What is JAZZ's current TTM revenue?+
TTM (trailing twelve months) revenue for Jazz Pharmaceuticals is calculated by summing the most recent four quarters of reported revenue. This provides a rolling annual figure that smooths out seasonal variation and is used in valuation metrics like price-to-sales.
How fast is Jazz Pharmaceuticals's revenue growing?+
Revenue growth is measured year-over-year by comparing each quarter to the same quarter in the prior year. This eliminates seasonal effects and shows underlying business momentum. Cannabis companies often see rapid growth in early stages as new markets open, then moderate as they mature.
Where does JAZZ's revenue come from?+
Jazz Pharmaceuticals's revenue comes from cannabis operations which may include cultivation, processing, distribution, and retail sales depending on their business model. Revenue can vary by state or province as new markets launch and existing markets mature.